Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non–Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial

Abstract

The final analysis of EMPHASIS-lung did not show a differential effect on PFS for erlotinib versus docetaxel stratified by VeriStrat status. Similarly, in the combined analysis, no significant treatment by VeriStrat status interaction was observed (interaction p = 0.24 for PFS and 0.45 for OS, stratified by study).

Apatinib monotherapy for advanced non‐small cell lung cancer after the failure of chemotherapy or other targeted therapy

“…11,12 In the CTONG0806 study, pemetrexed was administered as second‐line treatment in advanced non‐squamous NSCLC patients with wild‐type EGFR and the mPFS was 4.8 months . The ETOP study showed an mPFS of 4.1 months in advanced squamous cell NSCLC patients treated with docetaxel as second‐line setting . In our patient sample, the mPFS in squamous cell NSCLC patients was 5.5 months (95% CI 0–12.7) and in adenocarcinoma NSCLC patients 6.3 months (95% CI 0–12.8) as a second‐line setting.…”

“…For advanced NSCLC patients with or without EGFR mutations, EGFR‐tyrosine kinase inhibitors (TKIs) and chemotherapy are recommended as first‐line treatment, respectively . After the failure of first‐line therapy, second or third‐line treatment does not currently yield acceptable progression‐free‐survival (PFS) or overall survival (OS) . Third‐generation EGFR‐TKIs were not available in mainland China at the beginning of our research.…”

“…[4][5][6][7][8][9][10] After the failure of first-line therapy, second or third-line treatment does not currently yield acceptable progression-freesurvival (PFS) or overall survival (OS). [11][12][13] Thirdgeneration EGFR-TKIs were not available in mainland China at the beginning of our research.…”

Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

“…The VeriStrat test is also predictive for outcomes to epidermal growth factor receptor ( EGFR )‐targeted therapies in patient cohorts in whom the EGFR mutation status is wild type (WT) or unknown. Multiple studies have demonstrated that VeriStrat testing can predict outcome to erlotinib , gefitinib , and cetuximab , either as monotherapy or in combination with other treatments . A retrospective analysis of the LUX‐lung 8 study demonstrated that VeriStrat could also predict OS in patients with squamous cell carcinoma treated with afatinib (VS‐G median OS, 11.5 mo; VS‐P median OS, 4.7 mo; HR, 0.57; p = .0001) .…”

Evaluation of the VeriStrat ® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study

“…VeriStrat status can indicate the likelihood of a favorable or unfavorable prognosis, and may also predict treatment outcomes. Potential clinical utility of the VeriStrat test in NSCLC has been exhibited across a range of EGFR-targeted agents [17][18][19][20][21][22][23]. For example, in the phase III PROSE study, the VeriStrat test has shown prognostic and predictive utility for second-line erlotinib in patients with NSCLC, most of whom had wildtype or unknown EGFR mutation status [22].…”